New hope for chinese lung cancer patients with rare gene mutation
NCT ID NCT05195632
First seen Jan 07, 2026 · Last updated Apr 29, 2026 · Updated 20 times
Summary
This study tests a combination of two targeted drugs, encorafenib and binimetinib, in Chinese adults with a specific genetic mutation (BRAF V600E) in advanced non-small cell lung cancer that has spread. Participants must not have received prior treatment with similar drugs. The goal is to see if the combo shrinks tumors and is safe, with a small initial group checking for early side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Cancer Hospital
Beijing, China
-
Beijing Chest Hospital, Capital Medical University
Beijing, China
-
Chongqing University Cancer Hospital
Chongqing, China
-
First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
-
Fujian Medical University Union Hospital
Fuzhou, China
-
Fuzhou Tuberculosis Prevention and Control Hospital of Fujian Province (Fuzhou Pulmonary Hospital of Fujian)
Fuzhou, China
-
Guangdong Provincial People's Hospital
Guangzhou, China
-
Guangxi Medical University Affiliated Tumor Hospital
Nanning, China
-
Hainan General Hospital
Haikou, China
-
Harbin Medical University Cancer Hospital
Harbin, China
-
Henan Cancer Hospital
Zhengzhou, China
-
Liaoning Cancer Hospital & Institute
Shenyang, China
-
Linyi Cancer Hospital
Linyi, China
-
Peking University First Hospital
Beijing, China
-
Peking University Shenzhen Hospital
Shenzhen, China
-
Shandong Cancer Hospital
Jinan, China
-
Shanxi Provincial Cancer Hospital
Taiyuan, China
-
Sichuan Cancer Hospital
Chengdu, China
-
Sun Yat-sen University Cancer Center
Guangzhou, China
-
Taipei Veterans General Hospital
Taipei, Taiwan
-
The First Affiliated Hospital of Jinzhou Medical University
Jinzhou, China
-
The First Affiliated Hospital of Nanchang University
Nanchang, China
-
The First Hospital of China Medical University
Shenyang, China
-
The First Hospital of Jilin University
Changchun, China
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, China
-
The Northern Jiangsu People's Hospital
Yangzhou, China
-
The Second Hospital of Dalian University
Dalian, China
-
Tianjin Cancer Hospital Airport Hospital
Tianjin, China
-
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
-
Union Hospital Tongji medical college Huazhong University of Science and Technology
Wuhan, China
-
Xiangya Hospital Central South University
Changsha, China
-
Yantai Yuhuangding Hospital
Yantai, China
-
Zhejiang Cancer Hospital
Hangzhou, China
-
Zhejiang University School of Medicine, Sir Run Run Shaw Hospital
Hangzhou, China
Conditions
Explore the condition pages connected to this study.